Keywords
How to Cite
Abstract
The synthesis of new pharmacological molecules and their introduction into medical practice constitute a stringent, multistage, and complex fundamental system governed by international standards. Preclinical (in vitro, in vivo) and clinical trials (Phases I-IV), which determine the safety profile and therapeutic window of drugs, serve as the primary shield protecting patient lives. This study aims to comprehensively analyze the translational pathway of pharmaceutical agents from the laboratory bench to clinical application, addressing the ensuing pharmacokinetic and pharmacodynamic barriers alongside the molecular mechanisms required to overcome them. Based on prospective and retrospective analyses, the 5-year testing trajectory (2020-2025) of 120 novel pharmacological candidate molecules was investigated. During the preclinical stage, conducted under Good Laboratory Practice (GLP) standards, 70.8% of the molecules were rejected due to profound toxicity (unsatisfactory LD50 parameters) and poor bioavailability. In the clinical trials, executed in accordance with Good Clinical Practice (GCP) requirements, only 7.5% of the initial candidates successfully navigated all phases (I, II, III) to attain regulatory approval. Furthermore, 45% of the attrition observed in Phase II clinical trials was attributed to unanticipated hepatotoxic reactions within the human biological system and sub-optimal affinity for target receptors. The application of pharmacogenetic approaches and the consideration of individual metabolic phenotypes during drug testing augmented clinical trial efficacy by 28%, a finding confirmed via mathematical regression models. The results of this investigation establish a highly informative platform for implementing systemic modifications to the pharmacological screening algorithm and accurately assessing the risk-benefit ratio, thereby optimizing the duration and economic expenditures of clinical trials.
References
1. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill; 2021.
2. Dimasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47:20-33.
3. European Medicines Agency (EMA). Guideline on the implementation of Good Clinical Practice (GCP). London: EMA; 2017.
4. Food and Drug Administration (FDA). The Drug Development Process: Step by Step. Silver Spring, MD: FDA; 2018.
5. Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today. 2018;17(9-10):419-424.
6. Harrison RK. Phase II and phase III failures: 2013–2015. Nature Reviews Drug Discovery. 2016;15(12):817-818.
7. Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery. 2015;14(7):475-486.
8. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 2019;286(5439):487-491.
9. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. British Journal of Pharmacology. 2017;162(6):1239-1249.
10. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286.
11. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. 2014;3(8):711-715.
12. Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide. Translational Medicine Communications. 2019;4(1):18.
13. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery. 2014;13(6):419-431
14. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline, Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Geneva: ICH; 2016.
15. Zulfiqar AA, Andres E. Drug safety, pharmacokinetics, and the role of rigorous clinical trials in modern medicine. Journal of Clinical Pharmacology. 2021;61(3):289-301.